IX SIMPOSIO · SYMPOSIUM | 2024
BIOPSIA LÍQUIDA · LIQUID BIOPSY
EL CAMINO A LA ONCOLOGÍA DE PRECISIÓN · THE WAY TO PRECISION MEDICINE

25, 26 Y 27 DE ENERO · JANUARY 25th, 26th and 27th

INNOVATION IN THE CONTEXT OF NON-INVASIVE TESTS

#SimposioBiopsiaLiquida
www.simposiobiopsialiquida.com

Organizado por:
Organized by:

Universidad Francisco de Vitoria UFV Madrid


How many Liquid Biopsy patents were published in Europe BEFORE the 1st Symposium in Santiago ?


3


And patents AFTER the 1st Symposium?


418

LIQUID BIOPSY PATENTS THROUGH THE "CAMINO" TO ONCOLOGY PRECISION

(source: EspaceNet Patent Search)



IX SIMPOSIO · SYMPOSIUM | 2024
BIOPSIA LÍQUIDA · LIQUID BIOPSY
EL CAMINO A LA ONCOLOGÍA DE PRECISIÓN · THE WAY TO PRECISION MEDICINE

MIMARK

Biomarker development for gynaecological diagnostics and a software-based algorithm

rivercyte | The future of blood analysis.

Syngle cell isolation and Physical Phenotype characterization through imaging analysis

Altum sequencing

Versatile DNA detection assay combined with NGS and advance Bioinformatics

Cyclomics
next-gen liquid-biopsy diagnostics

Ultra sensitive CtDNA detection kit and AI platform to accelerate data interpretation

MIMARK

Gynecological fluids

are the next liquid biopsy in gynecology
to make pain-free, accessible and easy diagnostics

Marina Rigau, PhD MBA
CEO & Founder

Eva Colás, PhD
CSO & Founder

Antonio Gil, PhD MD
CMO & Founder

Vall d'Hebron Barcelona Campus Hospitalari
NA RA.
NAMAREL VENTURES
inveready
WILD CARD
eit Health
clave
WA4STEAM Women Angels for STEAM
innvierte

WomEC

an IVD immunoassay for endometrial cancer detection in uterine fluid

- 99% sensitivity
- 97% Negative Predictive Value
- Tested in + 600 patients

IX SIMPOSIO · SYMPOSIUM | 2024
BIOPSIA LÍQUIDA · LIQUID BIOPSY
EL CAMINO A LA ONCOLOGÍA DE PRECISIÓN · THE WAY TO PRECISION MEDICINE

Feel the difference





Kubánková et al., Biophysical Journal 2022





Soteriou et al., Nature Biomed Eng 2023

IX SIMPOSIO · SYMPOSIUM | 2024
BIOPSIA LÍQUIDA · LIQUID BIOPSY
EL CAMINO A LA ONCOLOGÍA DE PRECISIÓN · THE WAY TO PRECISION MEDICINE



empresa innovadora de base tecnológica reconocida por ANCES eibt

Altum Sequencing

“Delivering personalised oncology tests, transforming patients lives"

Hospital Universitario 12 de Octubre

uc3m Universidad Carlos III de Madrid

Fundación Investigación Biomédica Hospital Universitario 12 Octubre

LEGANÉS TECNOLÓGICO

 Jary 2024

IX SIMPOSIO · SYMPOSIUM | 2024
BIOPSIA LÍQUIDA · LIQUID BIOPSY
EL CAMINO A LA ONCOLOGÍA DE PRECISIÓN · THE WAY TO PRECISION MEDICINE

CyclomicsSeq - sequencing cfDNA at single-molecule resolution

Original sentence (sequence)

`Your cat is a furry animal`

Reading multiple times

```
Your cat is a funny animal
Your bat is a furry animal
-our cat is a furry animal
Your cat is a furry animal
```



✓ **Sensitive**
VAF 0.02%

✓ **Fast**
2 days

✓ **Flexible**
amplicons & cfDNA

Cyclomics

IX SIMPOSIO · SYMPOSIUM | 2024
BIOPSIA LÍQUIDA · LIQUID BIOPSY
EL CAMINO A LA ONCOLOGÍA DE PRECISIÓN · THE WAY TO PRECISION MEDICINE

25, 26 Y 27 DE ENERO · JANUARY 25th, 26th and 27th

INNOVATION IN THE CONTEXT OF NON-INVASIVE TESTS

#SimposioBiopsiaLiquida
www.simposiobiopsialiquida.com

Organizado por:
Organized by:

Universidad Francisco de Vitoria UFV Madrid

Dr. Eva Colás studied biology at the University of Barcelona and completed her PhD studies on endometrial cancer and gynaecological fluids. Using those fluids, she worked on the development of the first molecular diagnostic tool in endometrial cancer.

She was appointed Research Group leader in 2017, leading the Group of Biomedical Research in Gynecology at VHIR. There, they currently work on translational research in endometrial cancer, ovarian cancer, and endometriosis, aiming to impact better diagnosis and to evolve precision medicine on women's health.

After several years of top science in gynaecological fluids and endometrial cancer, Eva and her colleagues co-founded MiMARK, where she acts as CSO. MiMARK is a women's health, Women-led start-up that envisions Gynecological fluids as the next liquid biopsy in gynecology to make pain-free, accessible, and easy diagnostics.

Martin Kräter received his PhD in hematopoietic stem cell development in 2017 (Technical University Dresden). After moving to the Max Plank Institute for the Science of Light in Erlangen he was promoted to researcher group leader in microfluidic-based blood cell diagnostics.

Martin co-founded Rivercyte and is leading the R&D, where the research centers on exploring the physical properties of blood cells in physiological and pathological conditions, aiming at establishing those features as new biomarkers.

His work has been recognized by the young scientist award of the German Society for Cell Biology in 2019, the Medical Valley Award of the Bavarian Ministry of Economic Affairs, Regional Development and Energy in 2020, and the speakers award of the Lost-Voices Foundation in 2023.

Yanira Heredia is the CEO of Altum Sequencing.
She holds an industrial PhD in Biomedicine and a Master Degree in Computational Biology. Her work was mainly focused on developing novel NGS protocols to detect minimal residual disease in hematological malignancies.
In 2017 she was awarded with an international fellowship in the computational Biology Group at Dana Farber Hospital in Boston.

Prior to Altum, she spent four years in a biotech as responsible for the scientific and commercial strategy and leading clients partnership.
Later, in Altum, she conducted an industrial post-doctoral research focused on the optimization and validation of the technology patented by Altum.

Now, she is involved in the design and execution of the business strategy and supervising internal and external operations.

Alessio Marcozzi, holds a doctorate in Molecular Biology from Groningen University, is a co-founder and the Director of Research & Development at Cyclomics, a company that originated as a spin-off from the University Medical Center Utrecht. His professional journey includes significant work in phage display, genetic engineering, and sequencing technologies.

At Cyclomics, Marcozzi has played a pivotal role in the development of innovative cancer diagnostic methods, particularly focusing on liquid biopsy technologies. One of their key contributions is the development of CyclomicsSeq, a technique that significantly improves the accuracy of detecting circulating tumor DNA (ctDNA) in blood samples. This technique is vital for non-invasive tumor diagnostics and monitoring, offering a more sensitive biomarker for real-time cancer assessment.

The work of Marcozzi and his team at Cyclomics has been recognized through various achievements, including winning the Health Holland Venture Challenge in 2017, which acknowledged their advanced technology and was a testament to the potential of their DNA concatemerization technology for cancer liquid biopsy genetic testing.